The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Oncolytic Viruses and the Immune System: The Dynamic Duo
Open accessAbstract
Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach toward cancer treatment. This therapy takes advantage of the natural propensity of most tumor cells to be infected by specific OVs. Besides the direct killing potential (oncolysis), what makes OV administration attractive for the present cancer immunotherapeutic scenario is the capacity to induce two new overlapping, but distinct, immunities: anti-tumoral and anti-viral. OV infection and oncolysis naturally elicit both innate and adaptive immune responses (required for long-term anti-tumoral immunity); at the same time, the viral infection prompts an anti-viral response. In this review, we discuss the dynamic interaction between OVs and the triggered responses of the immune system. The anti-OV immunological events that lead to viral clearance and the strategies to deal with such potential loss of the therapeutic virus are discussed. Additionally, we review the immune stimulatory actions induced by OVs through different inherent strategies, such as modulation of the tumor microenvironment, the role of immunogenic cell death, and the consequences of genetically modifying OVs by arming them with therapeutic transgenes. An understanding of the balance between the OV-induced anti-tumoral versus anti-viral immunities will provide insight when choosing the appropriate virotherapy for any specific cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552
Optimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Marelli, G., Howells, A., Lemoine, N. R., & Wang, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00866 · Cited by 279
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Breitbach, C. J., Arulanandam, R., De Silva, N., Thorne, S. H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2687 · Cited by 258
Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy
Thorne, S. H., Negrin, R. S., & Contag, C. H. (2006) · Science · doi:10.1126/science.1121411 · Cited by 252
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
Ferguson, M. S., Lemoine, N. R., & Wang, Y. (2012) · Advances in Virology · doi:10.1155/2012/805629 · Cited by 231
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W., & Kroemer, G. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 231
Koks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N., & Van Gool, S. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 206
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.3013 · Cited by 205
Workenhe, S. T., & Mossman, K. L. (2014) · Molecular Therapy · doi:10.1038/mt.2013.220 · Cited by 203
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Serrano-del Valle, A., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 198
Measles virus causes immunogenic cell death in human melanoma
Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V, Scott, K., Peach, H., Phillips, R. M., Bond, J., Pandha, H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2011.205 · Cited by 187
Oncolytic viruses: a novel form of immunotherapy
Prestwich, R. J., Harrington, K. J., Pandha, H. S., Vile, R. G., Melcher, A. A., & Errington, F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1581 · Cited by 180
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.035 · Cited by 177
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
Roles of natural killer cells in antiviral immunity
Waggoner, S. N., Reighard, S. D., Gyurova, I. E., Cranert, S. A., Mahl, S. E., Karmele, E. P., McNally, J. P., Moran, M. T., Brooks, T. R., Yaqoob, F., et al. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.10.008 · Cited by 170
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A., & Vile, R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.194 · Cited by 167
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Dávola, M. E., & Mossman, K. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596006 · Cited by 166
Armed oncolytic viruses: A kick-start for anti-tumor immunity
de Graaf, J. F., de Vor, L., Fouchier, R. A. M., & van den Hoogen, B. G. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.03.006 · Cited by 165
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 163
Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1932 · Cited by 158 · cited 1×
“It has also been shown to remodel the TME and, when combined with immuno-checkpoint inhibitors, overcome resistance to immunotherapy.(11,99,106,107) As observed, cytokines can induce diverse pleiotropic effects to stimulate anti-tumor responses, but none is devoid of toxicity.”
BackgroundOncolytic Viruses: Priming Time for Cancer Immunotherapy
Russell, L., Peng, K. W., Russell, S. J., & Díaz, R. M. (2019) · BioDrugs · doi:10.1007/s40259-019-00367-0 · Cited by 158
Bommareddy, P. K., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1591875 · Cited by 155
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Martin, N. T., & Bell, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.001 · Cited by 154
Kowalsky, S. J., Liu, Z., Feist, M., Berkey, S. E., Ma, C., Ravindranathan, R., Dai, E., Roy, E. J., Guo, Z. S., & Bartlett, D. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.013 · Cited by 152
Garofalo, M., Saari, H., Somersalo, P., Crescenti, D., Kuryk, L., Aksela, L., Capasso, C., Madetoja, M., Koskinen, K., Oksanen, T., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.015 · Cited by 138 · cited 1×
“Cancer cell-derived EVs transporting oncolytic adenovirus (Ad5D24) exhibited a tumor-selective delivery in a lung carcinoma model.(28,29) In addition, tumor cell-derived microparticles, a specific type of vesicle (0.”
BackgroundIankov, I. D., Blechacz, B. R. A., Liu, C., Schmeckpeper, J., Tarara, J. E., Federspiel, M. J., Caplice, N. M., & Russell, S. J. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300020 · Cited by 137
Ahmed, A. U., Tyler, M. A., Thaçi, B., Alexiades, N. G., Han, Y., Ulasov, I. V., & Lesniak, M. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200161f · Cited by 137
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
LaRocca, C. J., & Warner, S. G. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0214-5 · Cited by 136
Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors
Muthana, M., Giannoudis, A., Scott, S. D., Fang, H., Coffelt, S. B., Morrow, F. J., Murdoch, C., Burton, J., Cross, N. A., Burke, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2349 · Cited by 133
Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley, A. C., & Dey, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00106 · Cited by 132
Ong, H. T., Hasegawa, K., Dietz, A. B., Russell, S. J., & Peng, K.-W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302880 · Cited by 131
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
Matveeva, O. V., & Chumakov, P. M. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2008 · Cited by 114
Li, R., Xiaohua, T., Li, Y., Zhang, H., Ma, R., Ji, T., Dong, W., Tong, T., Liu, Y., Chen, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.025 · Cited by 105
Yoon, A. R., Hong, J., Li, Y., Shin, H. C., Lee, H., Kim, H., & Yun, C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3900 · Cited by 102
Garofalo, M., Villa, A. M., Rizzi, N., Kuryk, Ł., Mazzaferro, V., & Ciana, P. (2018) · Viruses · doi:10.3390/v10100558 · Cited by 101
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 100
Adipose-derived Stem Cells as Therapeutic Delivery Vehicles of an Oncolytic Virus for Glioblastoma
Josiah, D. T., Zhu, D., Dreher, F., Olson, J. D., McFadden, G., & Caldas, H. (2009) · Molecular Therapy · doi:10.1038/mt.2009.265 · Cited by 98
Self-citationTGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
Han, J., Chen, X., Chu, J., Xu, B., Meisen, W. H., Chen, L., Zhang, L., Zhang, J., He, X., Wang, Q.-E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0894 · Cited by 98
Ilett, E. J., Bárcena, M., Errington‐Mais, F., Griffin, S. D. C., Harrington, K. J., Pandha, H., Coffey, M. C., Selby, P. J., Limpens, R. W. A. L., Mommaas, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3266 · Cited by 97
Foloppe, J., Kempf, J., Futin, N., Kintz, J., Cordier, P., Pichon, C., Findeli, A., Vorburger, F., Quéméneur, É., & Erbs, P. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.005 · Cited by 97
Patel, M. R., Dash, A., Jacobson, B. A., Ji, Y., Baumann, D. C., Ismail, K., & Kratzke, R. A. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0074-6 · Cited by 96
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
Liu, Z., Ge, Y., Wang, H., Ma, C., Feist, M., Ju, S., Guo, Z. S., & Bartlett, D. L. (2018) · Nature Communications · doi:10.1038/s41467-018-06954-z · Cited by 93
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Choi, A. H., O’Leary, M., Fong, Y., & Chen, N. G. (2016) · Biomedicines · doi:10.3390/biomedicines4030018 · Cited by 91
Qiao, J., Wang, H., Kottke, T. J., Díaz, R. M., Willmon, C. L., Hudacek, A. W., Thompson, J., Parato, K., Bell, J. C., Naik, J., et al. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303098 · Cited by 89
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Chen, C., Hutzen, B. J., Wedekind, M. F., & Cripe, T. P. (2018) · Oncolytic Virotherapy · doi:10.2147/ov.s145532 · Cited by 83
Haddad, D. R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00096 · Cited by 78
Ilett, E. J., Kottke, T., Thompson, J., Rajani, K. R., Zaidi, S. H. H., Evgin, L., Coffey, M. C., Ralph, C., Diaz, R., Pandha, H. S., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.70 · Cited by 77
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells
Kurokawa, C., Iankov, I. D., & Galanis, E. (2019) · Virus Research · doi:10.1016/j.virusres.2019.01.014 · Cited by 77
Tian, Y., Jiang, K., Wei, L., Barr, M. P., Xu, Q., Zhang, G., Ding, C., Meng, S., & Piao, H. (2018) · Europe PMC (PubMed Central) · Cited by 76
Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
Jha, B. K., Dong, B., Nguyen, C. T., Polyakova, I. V., & Silverman, R. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.112 · Cited by 73
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors
Escobar-Zarate, D., Liu, Y.-P., Suksanpaisan, L., Russell, S. J., & Peng, K.-W. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.55 · Cited by 68
Niemann, J., Woller, N., Brooks, J., Fleischmann-Mundt, B., Martin, N. T., Kloos, A., Knocke, S., Ernst, A. M., Manns, M. P., Kubicka, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11137-5 · Cited by 66
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
Havunen, R., Santos, J. M., Sorsa, S., Rantapero, T., Lumén, D., Siurala, M., Airaksinen, A. J., Cervera-Carrascón, V., Tähtinen, S., Kanerva, A., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.10.005 · Cited by 65
Denton, N. L., Chen, C., Hutzen, B. J., Currier, M. A., Scott, T., Nartker, B. A., Leddon, J. L., Wang, P.-Y., Srinivas, R., Cassady, K. A., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.10.001 · Cited by 59
Mooney, R., Majid, A. A., Batalla‐Covello, J., Machado, D., Liu, X., Gonzaga, J. M., Tirughana, R., Hammad, M., Dellinger, T. H., Lesniak, M. S., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.003 · Cited by 59
McGray, A. R., Huang, R.-Y., Battaglia, S., Eppolito, C., Miliotto, A. J., Stephenson, K. B., Lugade, A. A., Webster, G., Lichty, B. D., Seshadri, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0641-x · Cited by 57
Mendez, N., Herrera, V., Zhang, L., Hedjran, F., Feuer, R., Blair, S. L., Trogler, W. C., Reid, T. R., & Kummel, A. C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.08.010 · Cited by 55
Shao, X., Wang, X., Guo, X., Jiang, K., Ye, T., Chen, J., Fang, J., Gu, L., Wang, S., Zhang, G., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00436 · Cited by 55
Somma, S. D., Iannuzzi, C. A., Passaro, C., Forte, I. M., Iannone, R., Gigantino, V., Indovina, P., Botti, G., Giordano, A., Formisano, P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00564 · Cited by 53
Poxvirus oncolytic virotherapy
Torres-Domínguez, L. E., & McFadden, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1600669 · Cited by 48
Self-citationRamírez, M. R., García-Castro, J., Melen, G. J., González‐Murillo, Á., & Franco-Luzón, L. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66010 · Cited by 47
Ghonime, M. G., & Cassady, K. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0014 · Cited by 47
Felt, S. A., Droby, G. N., & Grdzelishvili, V. Z. (2017) · Journal of Virology · doi:10.1128/jvi.00461-17 · Cited by 46
Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses
Angarita, F. A., Acuña, S. A., Ottolino‐Perry, K., Zerhouni, S., & McCart, J. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.02.008 · Cited by 44
Draganov, D., Santidrián, A. F., Minev, I., Nguyen, D. H., Kilinc, M. O., Petrov, I. S., Vyalkova, A., Lander, E. B., Berman, M. H., Minev, B., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1829-z · Cited by 44
Mesenchymal Stem Cells and Cancer: Tumor-Specific Delivery Vehicles or Therapeutic Targets?
Dwyer, R. M., & Kerin, M. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.135 · Cited by 43
Yamano, T., Kubo, S., Fukumoto, M., Yano, A., Mawatari-Furukawa, Y., Okamura, H., & Tomita, N. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.31 · Cited by 43
Rojas, J. J., Sampath, P., Bonilla, B., Ashley, A., Hou, W., Byrd, D., & Thorne, S. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.017 · Cited by 42
Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy
Ebrahimi, S., Ghorbani, E., Khazaei, M., Avan, A., Ryzhikov, M., Azadmanesh, K., & Hassanian, S. M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25917 · Cited by 41
Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies
Khalil, I., Khechara, M. P., Kurusamy, S., Armesilla, A. L., Gupta, A., Mendrek, B., Khalaf, T., Scandola, M., Focarete, M. L., Kowalczuk, M. M., et al. (2018) · Molecules · doi:10.3390/molecules23102565 · Cited by 41
Aoyama, K., Kuroda, S., Morihiro, T., Kanaya, N., Kubota, T., Kakiuchi, Y., Kikuchi, S., Nishizaki, M., Kagawa, S., Tazawa, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14717-x · Cited by 39
Carrier Cell–mediated Delivery of a Replication-competent Adenovirus for Cancer Gene Therapy
Hamada, K., Desaki, J., Nakagawa, K., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300128 · Cited by 38
Melzer, M. K., Zeitlinger, L., Mall, S., Steiger, K., Schmid, R. M., Ebert, O., Krackhardt, A. M., & Altomonte, J. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.001 · Cited by 38
Targeting tumor vasculature through oncolytic virotherapy: recent advances
Merchan, J. R., & Toro, M. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66045 · Cited by 36
Sun, X., Han, H., Zhao, Gong, T., Zhi-RongZhang, & Sun, X. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27526 · Cited by 32
Francini, N., Cochrane, D., Illingworth, S., Purdie, L., Mantovani, G., Fisher, K., Seymour, L. W., Spain, S. G., & Alexander, C. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00189 · Cited by 24
Induction of Immunogenic Tumor Cell Death by Attenuated Oncolytic Measles Virus
Boisgerault, N. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000291 · Cited by 19
Lee, J. M., Ghonime, M. G., & Cassady, K. A. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.09.001 · Cited by 14
Cited by
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00541-y · Cited by 597
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50
Metadata
- Authors
- Lemos de Matos, A., Franco, L. S., & McFadden, G.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 17
- Pages
- 349-358
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2999300004
- Cited by
- 269
- References
- 91
- FWCI
- 20.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.